Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Morton Grove Pharmaceuticals, Inc.
483
•Morton Grove Pharmaceuticals, Inc.•March 26, 2014

Morton Grove Pharmaceuticals, Inc. – FDA 483, Mar 26, 2014

Record Details

During an inspection conducted from January 22, 2014, to March 26, 2014, the U.S. Food and Drug Administration (FDA) issued a Form FDA 483 to Morton Grove Pharmaceuticals, Inc. The inspection identified significant deviations from Current Good Manufacturing Practice (CGMP) regulations for human drug manufacturing. Key observations highlighted critical deficiencies in the company's quality control unit and laboratory operations. The firm's Quality Unit failed to adequately monitor quality systems, evidenced by the continued uncontrolled use of "trial" injections during chromatographic testing for drug release and stability, a practice previously cited in warning letters to other related facilities. Laboratory controls lacked scientifically sound procedures for these trial injections, which were not properly documented, reviewed, or subject to audit trails. Furthermore, raw data files could be deleted from computer systems by unauthorized personnel. Other notable issues included a failure to follow the stability testing program, incomplete investigations into out-of-specification results, and the quality unit's lack of authority to thoroughly investigate errors, such as recurrent product complaints regarding non-functioning spray actuators. Procedural changes were not adequately controlled, and production hold times were not appropriately established or tracked. Facility sanitation was also a concern, with mold observed in a hand dryer catch basin. Finally, deficiencies were noted in employee CGMP training and adherence to sanitation practices in manufacturing areas. Morton Grove Pharmaceuticals, Inc. is required to address these observations by implementing comprehensive corrective and preventive actions to ensure compliance with federal regulations.

Company
Morton Grove Pharmaceuticals, Inc.
Inspection date
March 26, 2014
Product type
Food
Office
Chicago District Office
Person
  • Brian D. Nicholson
View Company Profile

ID · c98ba2bb-0960-4258-91d8-955fb35acd68

Violation Codes1
FD&C Act 801(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Morton Grove Pharmaceuticals, Inc.
  • 483 - 2021-05-20May 20, 2021
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Morton Grove Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.